Over 40 years, YHEC has published hundreds of papers on a diverse range of topics. In this blog post, we take a closer look at the impact of one of our most highly cited papers: a paper published in 2012 in the Diabetic Medicine journal titled 'Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs'.

As YHEC celebrate four decades of innovation and growth during our 40th anniversary year, we look back on one of the partnerships that made this milestone possible. In this blog post, we take a closer look at our longstanding collaboration with the National Institute for Health and Care Excellence (NICE). To explore how that work has evolved, and why it matters, we spoke with Matthew Taylor and Hayden Holmes about some of the most challenging, controversial and rewarding projects they’ve worked on with NICE.

In the fast-paced world of healthcare analysis, transparent and rigorous data processing is crucial for building trust. Dr Joe Moss, Principal Statistician at YHEC, specialises in breaking down complex data challenges into elegant, defensible narratives, ensuring there is no "black box" when it comes to demonstrating product value. In this blog, we interview Joe to find out how he got into this role, what his day-to-day work looks like, and what he enjoys most about being part of YHEC.

A central pillar of the NHS 10-Year Health Plan for England is the concept of "neighbourhood health", an ambition to move care out of hospitals and back into our communities. In this blog, Director of NHS Consulting, Nick Hex, and Research Consultant, Hannah Ross, explore whether the neighbourhood health model can truly shift the dial on productivity and health inequalities, or if it remains an elusive panacea. They dig into the economic realities of this transition and ask a vital question: how do we ensure this new model delivers real value for money?

Real-world evidence is often presented as the answer to the limitations of traditional clinical trials. It can be faster to generate, more reflective of routine practice, and better suited to some decision contexts. However, these advantages do not remove the central challenge of evidence interpretation, such as distinguishing genuine treatment effects from misleading signals. In this blog, we explore the foundational biases of causal inference and how to integrate diverse data types to make defensible choices for health systems.

The move towards considering health equity more explicitly within health technology assessment is gaining international momentum. In this blog, I’ve brought together Hayden Holmes, Robert Malcolm, and Angel Varghese to discuss. Here you can read their discussion, where they share different perspectives on issues surrounding health inequalities and how methods, such as DCEA, can help to tackle them.

Is the minimally important change (MIC) still a reliable metric? With the scientific community currently debating the limitations of single-value thresholds in patient-reported outcomes, our latest research in the Journal of Patient-Reported Outcomes offers a timely perspective. In this blog, we share our findings and discuss what this shifting landscape means for patients and providers alike.